BACKGROUND: Glioblastoma (GBM) is the most common and fatal human brain tumor, with the worst prognosis. The aberrant microenvironment, enhanced by the activation of proangiogenic mediators such as hypoxia-inducible factor-1 alpha (HIF-1 alpha), vascular endothelial growth factor (VEGF), and their downstream effectors, sustain GBM malignancy. Proangiogenic signaling represents an attractive chemotherapeutic target. Recent evidence suggests a therapeutic benefit from aspirin (acetylsalicylic acid, or ASA) intake in reducing risk and cancer progression. METHODS: In the present study, human primary GBM- endothelial cells (ECs) were used to ascertain whether ASA could inhibit angiogenesis and improve cell sensitivity to drugs. The impact of ASA was observed by measuring cell viability, tube-like structure formation, migration, VEGF production, and proliferative, proangiogenic, and apoptotic modulators expression, such as HIF-1 alpha/VEGF/vascular endothelial growth factor receptor/(VEGFR)-1/VEGFR-2, Ras/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase, phosphoinositide 3-kinase/AKT signaling axis, and Bcl-2-associated X protein/B-cell lymphoma 2 (BCL-2) ratio. Furthermore, we evaluated the effect of ASA alone or in combination with temozolomide (TMZ), bevacizumab (BEV), and sunitinib (SUN). RESULTS: Our data reported that ASA affected GBM-EC viability, tube-like structure formation, cell migration, and VEGF releasing in a dose-dependent manner and that combined treatments with TMZ, BEV, and SUN synergized to counteract proangiogenic cell ability. mRNA expression analysis displayed a marked effect of ASA in reducing VEGF, VEGFR-1, HIF-1 alpha, RAS, mitogen-activated protein kinase kinase, AICT, and BCL-2, as well a combined anticancer effect of ASA together with TMZ, BEV, and SUN. Levels of HIF-1 alpha, VEGFR-2, Bcl-2-associated X protein, and BCL-2 protein expression confirmed a positive trend. CONCLUSIONS: ASA and antiangiogenic therapies showed synergetic anticancer efficacy in human primary GBM-ECs. Thus, the combination of conventional chemotherapy with ASA may offer a new strategy to counteract tumor malignancy.
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling / S. Navone, L. Guarnaccia, C. Cordiglieri, F.M. Crisa', M. Caroli, M. Locatelli, L. Schisano, P. Rampini, M. Miozzo, N. La Verde, L. Riboni, R. Campanella, G. Marfia. - In: WORLD NEUROSURGERY. - ISSN 1878-8750. - 120(2018 Dec), pp. E380-E391.
Titolo: | Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling |
Autori: | GUARNACCIA, LAURA (Co-primo) CAMPANELLA, ROLANDO (Penultimo) |
Parole Chiave: | Angiogenesis; Aspirin; Endothelial cells; Glioblastoma; HIF-1 alpha; VEGF |
Settore Scientifico Disciplinare: | Settore MED/27 - Neurochirurgia Settore BIO/10 - Biochimica |
Data di pubblicazione: | dic-2018 |
Rivista: | |
Tipologia: | Article (author) |
Data ahead of print / Data di stampa: | ago-2018 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.wneu.2018.08.080 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
1-s2.0-S1878875018318631-main.pdf | Publisher's version/PDF | Administrator Richiedi una copia |